SEC Form 4 · accession 0001640455-18-000013
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberlee C Drapkin
Officer — CFO and Treasurer
Period of report
Feb 1, 2018
Accepted (ET)
Feb 5, 2018 · 6:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $23.98 | Feb 1, 2018 | A | 97,500 | A | — | Feb 1, 2028 | Common Stock | 97,500 | 97,500 | D |
Explanation of responses
- F1The option will vest quarterly in 16 equal installments following January 1, 2018.